BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 37385561)

  • 21. The dilemma of monotherapy or combination therapy in community-acquired pneumonia.
    Vardakas KZ; Trigkidis KK; Apiranthiti KN; Falagas ME
    Eur J Clin Invest; 2017 Dec; 47(12):. PubMed ID: 29027205
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Moxifloxacin monotherapy versus beta-lactam-based standard therapy for community-acquired pneumonia: a meta-analysis of randomised controlled trials.
    An MM; Zou Z; Shen H; Gao PH; Cao YB; Jiang YY
    Int J Antimicrob Agents; 2010 Jul; 36(1):58-65. PubMed ID: 20400271
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Azithromycin plus β-lactam versus levofloxacin plus β-lactam for severe community-acquired pneumonia: A retrospective nationwide database analysis.
    Suzuki J; Sasabuchi Y; Hatakeyama S; Matsui H; Sasahara T; Morisawa Y; Yamada T; Yasunaga H
    J Infect Chemother; 2019 Dec; 25(12):1012-1018. PubMed ID: 31227381
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of guideline-concordant antibiotics and macrolide/β-lactam combinations in 3203 patients hospitalized with pneumonia: prospective cohort study.
    Asadi L; Eurich DT; Gamble JM; Minhas-Sandhu JK; Marrie TJ; Majumdar SR
    Clin Microbiol Infect; 2013 Mar; 19(3):257-64. PubMed ID: 22404691
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Beta-lactam plus macrolides or beta-lactam alone for community-acquired pneumonia: A systematic review and meta-analysis.
    Horita N; Otsuka T; Haranaga S; Namkoong H; Miki M; Miyashita N; Higa F; Takahashi H; Yoshida M; Kohno S; Kaneko T
    Respirology; 2016 Oct; 21(7):1193-200. PubMed ID: 27338144
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Comparison of the combination and quinolone therapy in community acquired pneumonia].
    Kılıç Soylar Ö; Kılınç O; Ellidokuz H
    Tuberk Toraks; 2015 Sep; 63(3):165-9. PubMed ID: 26523897
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibiotic Therapy for Adults Hospitalized With Community-Acquired Pneumonia: A Systematic Review.
    Lee JS; Giesler DL; Gellad WF; Fine MJ
    JAMA; 2016 Feb; 315(6):593-602. PubMed ID: 26864413
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibiotic treatment outcomes in community-acquired pneumonia.
    Çilli A; Sayıner A; Çelenk B; Şakar Coşkun A; Kılınç O; Hazar A; Aktaş Samur A; Taşbakan S; Waterer GW; Havlucu Y; Kılıç Ö; Tokgöz F; Bilge U
    Turk J Med Sci; 2018 Aug; 48(4):730-736. PubMed ID: 30119147
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Beta-Lactam Plus Macrolide for Patients Hospitalized With Community-Acquired Pneumonia: Difference Between Autumn and Spring.
    Kim Y; Jeon Y; Kwon KT; Bae S; Hwang S; Chang HH; Kim SW; Lee WK; Yang KH; Shin JH; Shim EK
    J Korean Med Sci; 2022 Nov; 37(45):e324. PubMed ID: 36413797
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials.
    Vardakas KZ; Siempos II; Grammatikos A; Athanassa Z; Korbila IP; Falagas ME
    CMAJ; 2008 Dec; 179(12):1269-77. PubMed ID: 19047608
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis.
    Asadi L; Sligl WI; Eurich DT; Colmers IN; Tjosvold L; Marrie TJ; Majumdar SR
    Clin Infect Dis; 2012 Aug; 55(3):371-80. PubMed ID: 22511553
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibiotic treatment of moderate-severe community-acquired pneumonia: design and rationale of a multicentre cluster-randomised cross-over trial.
    van Werkhoven CH; Postma DF; Oosterheert JJ; Bonten MJ
    Neth J Med; 2014 Apr; 72(3):170-8. PubMed ID: 24846935
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Usefulness of β-lactam and macrolide combination therapy for treating community-acquired pneumonia patients hospitalized in the intensive care unit: Propensity score analysis of a prospective cohort study.
    Ito A; Ishida T; Tachibana H; Nakanishi Y; Tokioka F; Yamazaki A; Washio Y; Irie H; Otake T
    J Infect Chemother; 2021 Oct; 27(10):1447-1453. PubMed ID: 34147355
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Beta-lactam versus beta- lactam/macrolide therapy in pediatric outpatient pneumonia.
    Ambroggio L; Test M; Metlay JP; Graf TR; Blosky MA; Macaluso M; Shah SS
    Pediatr Pulmonol; 2016 May; 51(5):541-8. PubMed ID: 26367389
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of Doxycycline for Mild-to-Moderate Community-Acquired Pneumonia in Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Choi SH; Cesar A; Snow TAC; Saleem N; Arulkumaran N; Singer M
    Clin Infect Dis; 2023 Feb; 76(4):683-691. PubMed ID: 35903011
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fluoroquinolones in community-acquired pneumonia: guide to selection and appropriate use.
    Frei CR; Labreche MJ; Attridge RT
    Drugs; 2011 Apr; 71(6):757-70. PubMed ID: 21504252
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Respiratory Fluoroquinolones Monotherapy vs. β-Lactams With or Without Macrolides for Hospitalized Community-Acquired Pneumonia Patients: A Meta-Analysis.
    Liu S; Tong X; Ma Y; Wang D; Huang J; Zhang L; Wu M; Wang L; Liu T; Fan H
    Front Pharmacol; 2019; 10():489. PubMed ID: 31139081
    [No Abstract]   [Full Text] [Related]  

  • 38. The science of selecting antimicrobials for community-acquired pneumonia (CAP).
    File TM
    J Manag Care Pharm; 2009 Mar; 15(2 Suppl):S5-11. PubMed ID: 19236135
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of Combined β-Lactam/Macrolide Therapy on Mortality According to the Microbial Etiology and Inflammatory Status of Patients With Community-Acquired Pneumonia.
    Ceccato A; Cilloniz C; Martin-Loeches I; Ranzani OT; Gabarrus A; Bueno L; Garcia-Vidal C; Ferrer M; Niederman MS; Torres A
    Chest; 2019 Apr; 155(4):795-804. PubMed ID: 30471269
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Survival benefit associated with clarithromycin in severe community-acquired pneumonia: A matched comparator study.
    Kyriazopoulou E; Sinapidis D; Halvatzis S; Velissaris D; Alexiou N; Kosmas V; Adami ME; Kyprianou M; Kyprianou A; Stefos A; Lada M; Koutoukas P; Pavlaki M; Kyriakoudi A; Makina A; Gogos C; Niederman MS; Giamarellos-Bourboulis EJ
    Int J Antimicrob Agents; 2020 Jan; 55(1):105836. PubMed ID: 31704213
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.